New Drug for Kaposi Sarcoma

Kaposi sarcoma treatment gets Breakthrough Therapy designation

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to pomalidomide (Pomalyst®), a thalidomide analogue, for the treatment of patients with Kaposi sarcoma. Breakthrough Therapy is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy.

Pomalidomide is being investigated as a potential treatment for patients with HIV-positive Kaposi sarcoma who have previously received systemic chemotherapy as well as in patients with HIV-negative Kaposi sarcoma. There are currently no FDA-approved treatments for HIV-positive patients who are refractory or intolerant of systemic chemotherapy.

Read Dr. Heymann's analysis of new pitfalls in the diagnosis of Kaposi sarcoma in DW Insights and Inquiries.

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.